

HBDA QUARTERLY NEWSLETTER

Fall Edition 2021

Rick Dinkins, Chairman

Volume 51

Vicki Jackson, Executive Director

Table of Contents

Cover Page

Words from the Chair

Page 2

Camp Harvest 2021

Page 3

Camp Harvest 2021

Page 4

Camp Harvest 2021

Page 8

Golf Tournament 2021

Page 9

2022 Annual Meeting Save the Date

Page 10

Year End Luncheon Save the Date

Page 11

Message from HBDA

Page 15

Upcoming HBDA Events

Page 16

HBDA Information & Birthdays



Hemophilia and Bleeding
Disorders of Alabama, Inc.

Staff

Executive Director

Vicki Jackson

Consumer Relations Manager

Amanda Jennings

Board Members

Rick Dinkins - Chairman

Jared McLaughlin - Vice Chair

Van Rushton - Treasurer

Blake Harris - Board Member

Brian Ward - Past President

Chris Blair - Past President

Words from the Chair

Greetings,

As November rolls into December the holiday season is fast upon us! This time of year, YOUR HBDA organization is wrapping up 2021 and, from my perspective, it has been a remarkable year.

While COVID 19 is still lurking (and will periodically raise up again), the year has been largely uneventful except for the movement of this year's Annual Meeting to March 2022. Camp Clot Not was very successful, our manufacturer seminars continued to provide the latest and greatest information to you, the annual Golf Tournament was outstanding. Next up is the annual Year End Luncheon, and some much-needed down time for the staff.

The big challenge this year has been to manage a compressed schedule of programs and to keep our sponsors informed as we had to adjust our efforts to meet COVID restrictions. Fortunately, that has seamlessly happened thanks to Vicki, Amanda, and a host of volunteers. Hopefully, 2022 will return to "NORMAL."

The organization is on solid financial ground as we have closely monitored expenses and scaled back some programs so as "to get the most bang for the buck." This has happened behind the scenes and from a consumer perspective, largely unnoticed.

Next year will see some changes as we look to answer the "What's Next" question. We do what we do extremely well and very efficiently. Our goal is to not get too comfortable and forget the need to grow and stretch ourselves. Lots more to follow as the Board looks to the future.

From the Board, have a great Thanksgiving and Christmas and an exciting New Year. Blessings to All!

Rick Dinkins
Chairman



CAMP HARVEST 2021

CHILDREN'S HARBOR ON LAKE MARTIN

30+ Dedicated Volunteers!

50 Pairs of Scissors!

20 Rolls of Packing Tape!

25+ Industry Friends!

1 Fuzzy Lemur and so much more!

Camp Harvest is a labor of love by the women of HBDA and their volunteers! The above list is only a mere sampling of what and who it takes to make our Family Fall Camp a huge success.

Many months go into the planning stages of this weekend of fellowship and education, to provide families and friends of Alabama's bleeding disorders community, the most up-to-date information available, with a little fun thrown in!

Friday evening, the eager family campers arrived at beautiful Children's Harbor on Lake Martin and were greeted by Vicki, Brenda and Leslie who shared with them the exciting events that would be presented throughout the weekend.

After almost two years being apart because of Covid, old friendships were embraced, and new friendships began! A hearty dinner, roaring campfire with marshmallows and a hot chocolate, apple cider bar wrapped up the evening and our sleepy campers made their way to bed.

Saturday dawned bright and beautiful as our members joined together for breakfast and fellowship. Bayer's educational program featured a patient advocate who shared his story about growing up with Hemophilia.



CAMP HARVEST 2021

HBDA kept the kids entertained while the parents attended the informative sessions with Brandon Young's "Country Boy Fishing," relay races, arts and crafts and many other activities.

Takeda's speaker, Erin Weigel talked about overcoming adversity, not to be afraid of living life fully and the benefits of treating prophylactically.

In between programs, HBDA produced their very own version of "Halloween Chef Wars," featuring the wild and crazy antics of Leslie Bailey and Lee Hall! Assigned to produce their scariest clown nightmare, they both turned out masterpieces...well, maybe not quite masterpieces! LOL! Lee won round 1 and then it was on like Donkey Kong for round two later that evening!

Octapharma hosted renowned Dr. Tami Singleton at our lunch session, who eloquently spoke about previously untreated patients with Hemophilia A, inhibitors, and the NuProtect Study.

During the afternoon educational session for their parents and caregivers, the kids divided up into two teams and competed in the "Haunted Golf Cart Challenge!" This hilarious contest resulted in bragging rights for the winning side and a crisp ten-dollar bill for each team member!



CAMP HARVEST 2021

Saturday afternoon our families, volunteers and sponsors celebrated the season at our annual Fall Festival!

A family pumpkin contest, Tickled Pink petting zoo, Toxic Meltdown, a photo booth, bouncy houses, face painting, games of all sorts and the magical characters Elsa, Anna, Captain America, and Spiderman made it an afternoon of fun, family bonding and building lifelong friendships!

A costume contest and the judging of the decorated golfcarts, along with a yummy dinner, put a big smile on everybody's face and gave them a full tummy!

Round two of "Halloween Chef Wars" finished out the evening with members of our community working with our "Chefs," to carve a pumpkin of perfection! Once again, Lee's team won, but Leslie's team gave him a run for the money!

Sunday dawned in glorious splendor and CSL Behring's speaker, Pete, talked about how he uses positivity to navigate through life's challenges while living with Hemophilia.

Genentech enlightened us about Hemlibra with their speaker APRN Sophia Miranda.

As this amazing weekend came to a close, our families shared with us they were so grateful to be able to get together and bond with their peers, while learning about all that is new in the world of Bleeding Disorders.

It can be said that definitely, "A good time was had by all!"

"Families and friends form some of the closest of bonds you will ever experience. It is almost impossible for you to lead a happy life without support from these important groups of people."

— Jeffrey Dawson

Until 2022, be blessed!



A **ONCE-WEEKLY** TREATMENT OPTION FOR HEMOPHILIA B.




HOW DOES
THIS FACTOR IN?

To find out about a prescription
option, talk to your doctor or visit
[OnceWeeklyForHemophiliaB.com](https://www.OnceWeeklyForHemophiliaB.com)

CAN YOU SOLVE **FOR A DIFFERENT** **HEMOPHILIA A** **TREATMENT?**

Test your HEMLIBRA knowledge



ACROSS

1. Wine barrel
5. Deep fissures
11. Mideast gulf port
12. District
13. Ripped
14. Familiar with
15. Mean
17. Roost
18. The #1 prescribed prophylaxis for hemophilia A*

*According to IQVIA claims data from various insurance plan types from October 2019 to November 2020 and accounts for usage in prophylaxis settings in the US.

21. Calendar divs.
22. Regret
23. Banquet hosts (abbr.)
26. International travel necessity
28. Check out the _____ treated bleeds data with HEMLIBRA
31. Number of dosing options HEMLIBRA offers

† Number of people with hemophilia A treated as of February 2021.

32. Small hole in lace cloth
35. Central Plains tribe
36. Melodic
37. Towering
38. Reduce
39. Spanish cheers

DOWN

1. Memorable, as an earworm
2. Devotee
3. Medical fluids
4. Prepare to propose, perhaps
5. PC's "brain"
6. Owns
7. Concert venue
8. See Medication Guide or talk to your doctor about potential _____ effects
9. Winter hrs. in Denver and El Paso
10. HEMLIBRA is the only prophylactic treatment offered this way under the skin

16. Pre-Euro currency in Italy
19. Subway alternative
20. Relax
23. Human
24. New Orleans cuisine
25. Mentally prepares
26. Collared shirts
27. Instagram post
28. Ardent enthusiasm
29. Brontë heroine Jane
30. Old Portuguese coins
33. Opposite of WNW
34. _____ thousand patients have been treated with HEMLIBRA worldwide†

SOLUTIONS

Across: 1. cask, 5. chasms, 11. Aden, 12. parish, 13. tore, 14. used to, 15. cruel, 17. nest, 18. HEMLIBRA, 21. yrs, 22. rue, 23. MCS, 26. passport, 28. zero, 31. three, 32. eyelid, 35. Ctore, 36. arose, 37. tall, 38. lessen, 39. oles
Down: 1. catchy, 2. adorer, 3. serums, 4. kneel, 5. CPU, 6. has, 7. arena, 8. side, 9. MSTs, 10. shot, 16. lira, 19. bus, 20. rest, 23. mortal, 24. Creole, 25. steels, 26. polos, 27. photo, 28. zeal, 29. Eyre, 30. Reis, 33. ESE, 34. ten

Discover more at [HEMLIBRA.com/answers](https://www.hemlibra.com/answers)

INDICATION & IMPORTANT SAFETY INFORMATION

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- **Thrombotic microangiopathy (TMA)**, a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events)**, which may form in blood vessels in your arm, leg, lung, or head

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including **Serious Side Effects**.



Medication Guide
HEMLIBRA® (hem-lee-bruh)
(emicizumab-kxwh)
injection, for subcutaneous use

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.

HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
 - confusion
 - weakness
 - swelling of arms and legs
 - yellowing of skin and eyes
 - stomach (abdomen) or back pain
 - nausea or vomiting
 - feeling sick
 - decreased urination
- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
 - swelling in arms or legs
 - pain or redness in your arms or legs
 - shortness of breath
 - chest pain or tightness
 - fast heart rate
 - cough up blood
 - feel faint
 - headache
 - numbness in your face
 - eye pain or swelling
 - trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

See “What are the possible side effects of HEMLIBRA?” for more information about side effects.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.

HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.**
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.

- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. **Do not** give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the possible side effects of HEMLIBRA?

- See “What is the most important information I should know about HEMLIBRA?”

The most common side effects of HEMLIBRA include:

- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain

These are not all of the possible side effects of HEMLIBRA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store HEMLIBRA?

- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.

Keep HEMLIBRA and all medicines out of the reach of children.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

What are the ingredients in HEMLIBRA?

Active ingredient: emicizumab-kxwh

Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.

Manufactured by: Genentech, Inc., A Member of the Roche Group,
1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No. 1048

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
©2018 Genentech, Inc. All rights reserved.

For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
This Medication Guide has been approved by the U.S. Food and Drug Administration
Revised: 10/2018



HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
©2021 Genentech USA, Inc. All rights reserved. M-US-00011998(v1.0) 08/21

Genentech
A Member of the Roche Group

HBDA GOLF TOURNAMENT 2021

ROBERT TRENT GOLF TRAIL AT CAPITOL HILL

HBDA KNOWS HOW TO “Tee It Up!”

This year's tournament was no exception to the rule. Once again, we were honored to have one of our biggest supporters attend our tournament! Dr. David Bronner and his team was on hand to help raise awareness and funds for Alabama's Bleeding Disorders Community.

The Robert Trent Jones Golf Course at Capitol Hill graciously opened its doors once again for our golfers and we were blessed with picture perfect weather!

Pro golfer, Perry Parker joined us for this afternoon of comradery on the pristine greens. Having Hemophilia himself, he brings to the game the notion that a bleeding disorder does not have to “define” who you are, it's just what you have. His inspiring approach to life could be a lesson to us all!

Our participating teams had a blast! Friendly, and sometimes a bit competitive golfing, fabulous food, unique raffle baskets to bid on and some awesome surprises, made their day outstanding!

HBDA does not put on an event of this caliber without a little help from our friends. We are very grateful to our industry partners, volunteers and friends who make this exciting fund-raiser a huge success each year!

Have a great rest of 2021 and we look forward to seeing you again in 2022!



HBDA Annual Meeting 2022

The HBDA Annual Meeting will be held at the Embassy Suites Hotel and Conference Center in Montgomery, AL. Information and registration forms will be sent out in the near future.
Make plans now to attend!

Date: March 11 - 13, 2022



**EMBASSY
SUITES**
by HILTON™

Montgomery - Hotel & Conference Center

What to Expect:

Top Keynote Speakers

Exhibits/Displays from Industry Partners

Current Educational Information

Inspirational and Interactive Sessions

You are invited to attend the:
HBDA Year End Educational and Display Event
December 11, 2021

11 AM – 2 PM
Embassy Suites Hotel Montgomery
300 Tallapoosa Street
Montgomery, AL 36104

Buffet Luncheon
Displays with our Industry Sponsors

Advanced reservations are required by November 26, 2021 for you to be confirmed and included in this event. Walk-ins cannot be accepted, so please plan ahead. A confirmation letter will be sent to you to confirm your reservation. (If you do not receive a confirmation letter within 7 business days of your reservation, please contact us immediately).

Consumer Members may reserve attendance by calling (334) 478-7822 or by emailing your reservation to hbdaeevents@gmail.com. Reservation must include names of all attendees and the ages of all attendees under 18.

Industry Members will be reserved through their sponsorship with an HBDA staff member.

CONSUMER MEMBER

Any person diagnosed with Hemophilia (A or B), vonWillebrand's Disease, or any other bleeding or clotting disorder, including any person who is a diagnosed carrier. Parents or legal guardians of a minor affected consumer member and any other minor family member(s) (people living in the same household) qualify as consumer members. An adult affected consumer member can qualify their minor children and their spouse, significant other OR ONE other adult so long as that adult does not qualify as an industry member, and that they reside in the same household with the affected adult member.

INDUSTRY MEMBER

Any person employed by or representing a pharmaceutical company, specialty pharmacy or any other for-profit business that earns any revenue from serving the bleeding disorders community. All adult members of an industry members' family (people living in the same household) are considered industry members except for any family member affected by a bleeding disorder, as well as any minor siblings living in the same household.

The cost for additional participants, outside the above Membership criteria, will be \$25.00 per person for children under 8 and \$45.00 per person ages 8 and older.



**Hemophilia and Bleeding
Disorders of Alabama, Inc.**



On behalf of the Staff and Board of HBDA, we wish you a very Merry Christmas and a Happy New Year! Thank you for your continued support of our organization and we look forward to serving you in 2022! God Bless You and your families!

First Choice
Home Infusion
Specialty Pharmacy

www.firstchoiceiv.com
1-866-665-3244

First Choice Home Infusion/Specialty Pharmacy

Dedicated partner in infusion and specialty pharmacy services

- At home delivery
- Personalized service
- HTC coordination
- Dedicated pharmacist support
- Home nursing coordination
- All needed supplies
- Nurse educators
- Insurance support services
- Copay assistance programs

Need more information? Call, text, or email

Mark Osborne
615-351-3604
mark@firstchoiceiv.com

JD Weir, RN
251-604-8832
john@firstchoiceiv.com

Shannon Kelley, RN
205-389-3201
shannon@firstchoiceiv.com

Make First Choice your first choice



LIFE HAPPENS

AND ADVATE WILL BE THERE WHEN IT DOES

*In clinical trials, ADVATE demonstrated the ability to help prevent bleeding episodes using a prophylaxis regimen.

Not an actual patient.

ADVATE has over 15 years of treatment experience in the real world and provides clinically proven bleed protection* for patients with hemophilia A.¹


[Antihemophilic Factor (Recombinant)]
REAL LIFE. REAL BLEED PROTECTION.*

AdvateRealLife.com

Prophylaxis with ADVATE prevented bleeds¹

The ability of ADVATE to treat or prevent bleeds was evaluated in a clinical study using a standard prophylaxis, pharmacokinetic driven prophylaxis, and on-demand treatment.

53 previously treated patients (PTPs) with severe to moderately severe hemophilia A were analyzed. For the first 6 months of the study, patients received on-demand treatment. For the following 12 months of the study, patients received either standard prophylaxis every 48 hours or a pharmacokinetic-driven prophylaxis every 72 hours. The primary goal of the study was to compare annual bleeding rates between those receiving prophylaxis treatment and those receiving treatment on-demand. The number of bleeds per year for the 2 prophylaxis regimens were comparable.

- Those patients experienced a median of 1 overall bleed per year on either prophylaxis treatment vs 44 overall bleeds per year with on-demand treatment.[†] This represented a 98% reduction in overall bleeds per year.
- Zero bleeds were reported in 42% of patients (22 out of 53 patients) during 12 months on prophylaxis

[†]Median is the middle number in a group of numbers arranged from lowest to highest.

ADVATE Important Information

What is ADVATE?

- ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia).
- ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Your healthcare provider (HCP) may give you ADVATE when you have surgery.
- ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Who should not use ADVATE?

Do not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your HCP if you are pregnant or breastfeeding because ADVATE may not be right for you.

What should I tell my HCP before using ADVATE?

Tell your HCP if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.

What should I tell my HCP before using ADVATE? (continued)

- Are or become pregnant. It is not known if ADVATE may harm your unborn baby.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What important information do I need to know about ADVATE?

- You can have an allergic reaction to ADVATE. Call your HCP right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.
- Do not attempt to infuse yourself with ADVATE unless you have been taught by your HCP or hemophilia center.

What else should I know about ADVATE and Hemophilia A?

- Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Talk with your HCP to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

What are possible side effects of ADVATE?

- Side effects that have been reported with ADVATE include: cough, headache, joint swelling/aching, sore throat, fever, itching, unusual taste, dizziness, hematoma, abdominal pain, hot flashes, swelling of legs, diarrhea, chills, runny nose/congestion, nausea/vomiting, sweating, and rash. Tell your HCP about any side effects that bother you or do not go away or if your bleeding does not stop after taking ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Important Facts about ADVATE on the following page and discuss with your HCP.

For Full Prescribing Information, visit www.ADVATE.com.

Reference: 1. ADVATE Prescribing Information.

Copyright © 2020 Takeda Pharmaceutical Company Limited, 300 Shire Way, Lexington, MA 02421. 1-800-828-2088. All rights reserved.

TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.

ADVATE is a registered trademark of Baxalta Incorporated, a Takeda company. US-ADV-0101v1.0 05/20





[Antihemophilic Factor (Recombinant)]

Important facts about

ADVATE [Antihemophilic Factor (Recombinant)]

This leaflet summarizes important information about ADVATE. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about ADVATE. If you have any questions after reading this, ask your healthcare provider.

What is the most important information I need to know about ADVATE?

Do not attempt to do an infusion to yourself unless you have been taught how by your healthcare provider or hemophilia center.

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing ADVATE so that your treatment will work best for you.

What is ADVATE?

ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia). The product does not contain plasma or albumin. Hemophilia A is an inherited bleeding disorder that prevents blood from clotting normally.

ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A.

Your healthcare provider may give you ADVATE when you have surgery. ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

Who should not use ADVATE?

You should not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your healthcare provider if you are pregnant or breastfeeding because ADVATE may not be right for you.

How should I use ADVATE?

ADVATE is given directly into the bloodstream.

You may infuse ADVATE at a hemophilia treatment center, at your healthcare provider's office or in your home. You should be trained on how to do infusions by your healthcare provider or hemophilia treatment center. Many people with hemophilia A learn to infuse their ADVATE by themselves or with the help of a family member.

Your healthcare provider will tell you how much ADVATE to use based on your weight, the severity of your hemophilia A, and where you are bleeding.

You may have to have blood tests done after getting ADVATE to be sure that your blood level of factor VIII is high enough to clot your blood.

Call your healthcare provider right away if your bleeding does not stop after taking ADVATE.

What should I tell my healthcare provider before I use ADVATE?

You should tell your healthcare provider if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.
- Are pregnant or planning to become pregnant. It is not known if ADVATE may harm your unborn baby.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What are the possible side effects of ADVATE?

You can have an allergic reaction to ADVATE.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Side effects that have been reported with ADVATE include:

cough	headache	joint swelling/aching
sore throat	fever	itching
unusual taste	dizziness	hematoma
abdominal pain	hot flashes	swelling of legs
diarrhea	chills	runny nose/congestion
nausea/vomiting	sweating	rash

Tell your healthcare provider about any side effects that bother you or do not go away

These are not all the possible side effects with ADVATE. You can ask your healthcare provider for information that is written for healthcare professionals.

What else should I know about ADVATE and Hemophilia A?

Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ADVATE for a condition for which it is not prescribed. Do not share ADVATE with other people, even if they have the same symptoms that you have.

The risk information provided here is not comprehensive. To learn more, talk with your health care provider or pharmacist about ADVATE. The FDA-approved product labeling can be found at www.ADVATE.com or 1-877-825-3327.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

©2020 Takeda Pharmaceutical Company Limited. 300 Shire Way, Lexington, MA 02421. 1-800-828-2088. All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. ADVATE is a registered trademark of Baxalta Incorporated, a Takeda company.

Patented: see <https://www.takeda.com/en-us/patents/>

U.S. License No. 2020
Issued: 12/2018

US-ADV-0030v1.0 02/20





JIVI®

ADYNOVATE®

PK (Pharmacokinetics) Study Data



Talk to your doctor
about the study.




Scan the QR code to learn more
about PK at **UnderstandingPK.com**

**** 2021 - 2022 EVENTS ****

<u>Date of Event:</u>	<u>Event:</u>	<u>Event Location:</u>
December 11, 2021	Year End Luncheon	Embassy Suites Mgm
March 11 - 13, 2022	Annual Meeting	Embassy Suites Mgm

More information will be coming out soon!



CLOT Line Assistance Program

Members:

If you are going through a difficult time, please remember, your HBDA family is here for you!

If you have been affected by COVID-19, or if you need assistance purchasing school supplies for your kids, please reach out to us.



HBDA INFORMATION

Address: 917 W Osceola Street, Wetumpka, AL 36092

Phone: (334) 478-7822

Fax: (334) 478-7824

Website: www.hbda.us

Facebook: www.facebook.com/hbda4u



BIRTHDAY BLESSINGS

November

Jennifer Anderson
Brynlee White
Katie Lee
Cameron Jones
Casey Sanders
Laura Pitman
Trace Lee
Chelynn Pargo
Robin Blair
Brayden Botts
Quintez Renfroe
Myra Cooper
Patsy Lewis
Makaylie Kelley
Grace Chung
Ciara Pargo
Jason Branch
Alexandra Hall
Fantine Martin
Ed Leathers

December

Joseph Clarke
Mary Cathrine Noa
Ty Zucco
Tricia Watts
Debby Dinkins
Camdyn Pressley
Kimberly Wood
Daniel Botts
Cheyenne Warren
Dawson Findley
Amanda Jennings
Michael McElhaney
Leslie Bailey
TJ Nicholson
Kelly Champagne

January

Madilynn Clarke
Nathan Sanders
Mary Beth Clarke
David Hall
Marcus Chung
Robert Masline
Honour Zucco
Jayla Lewis
Amare Banks
Takiya Wells
Bentley Golden
Lauren Killgore
Erin Cotham
Donna Bate
Bryan Utterback
Carolann Sorrells
Jeremy Jones